Updated Recommendation
A new evidence synthesis was published:2023, Therapeutics and COVID-19: living guideline, 10 November 2023.
View latest version (2023)Bibliographic information
Recommendation
We recommend not to use ivermectin in patients with COVID-19 except in the context of a clinical trial
Recommended against
Strong
Certainty of evidence
Very low
Notes and Remarks
Remark: This recommendation applies t o patients with an y disease se verity and an y duration of symptoms. A recommendation t o only use a drug in the setting o f clinical trials is appr opriate when ther e is very low certainty evidence and futur e research has a lar ge potential for reducing unc ertainty about the eff ects o f the in tervention and f or doing so at r easonable c ost.
Resources and other considerations
Also Featured In
This recommendation also appears in the following guidelines:
Therapeutics and COVID-19: living guideline, 31 March 2021.
Therapeutics and COVID-19: living guideline, 6 July 2021.
Therapeutics and COVID-19: living guideline, 24 September 2021.
Therapeutics and COVID-19. Living guideline. 7 December 2021
Therapeutics and COVID-19: living guideline, 14 January 2022.
Therapeutics and COVID-19: living guideline, 3 March 2022.
Therapeutics and COVID-19: living guideline, 22 April 2022.
Therapeutics and COVID-19: living guideline, 14 July 2022.
Therapeutics and COVID-19: living guideline, 16 September 2022.